Mark M. Moasser

10.2k citations
115 papers · 7.7k · 3 hit papers · h-index 40

Impact in

  • Oncology top 0.5%
    • HER2/EGFR in Cancer Research
    • Cancer-related Molecular Pathways
    • Peptidase Inhibition and Analysis
    • Cancer Treatment and Pharmacology
    • Monoclonal and Polyclonal Antibodies Research

Papers in

    • HER2/EGFR in Cancer Research 40
    • Cancer Treatment and Pharmacology 15
    • Glycosylation and Glycoproteins Research 8
    • Retinoids in leukemia and cellular processes 8

Mark M. Moasser

111 papers receiving 7.5k citations

Mark M. Moasser's Hit Papers

The epidermal growth factor receptor family: Biology driving targeted therapeutics 2008 · 610 citations
6100+6+12Years since publication250500750

Peers

Mark M. Moasser
Comparison fields: 5 of 123
  • Oncology 3.8k
  • Radiology, Nuclear Medicine and Imaging 1.4k
  • Cancer Research 779
  • Genetics 527
  • Pulmonary and Respiratory Medicine 1.5k
Replace Tona M. Gilmer with:
Tona M. Gilmer United States
Stephen R. Wedge United Kingdom
David W. Fry United States
Antonella De Luca Italy
Ron Bose United States
Wells A. Messersmith United States
Federico Rojo Spain
Joaquı́n Arribas Spain
Rita Nahta United States
Ingrid A. Mayer United States
Mark M. Moasser relative to Tona M. Gilmer United States Tona M. Gilmer's profile →
Citations per field
00.5×3.3×
Tona M. Gilmer · 1×
Citations per year

Countries citing papers authored by Mark M. Moasser

Since Specialization
Citations

This map shows the geographic impact of Mark M. Moasser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark M. Moasser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark M. Moasser more than expected).

Fields of papers citing papers by Mark M. Moasser

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark M. Moasser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark M. Moasser. The network helps show where Mark M. Moasser may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark M. Moasser, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark M. Moasser Line = papers co-authored together Mark M. Moasser links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 115 papers — load more, or switch the sort, to bring in the rest.

#Work
1
The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis
Hit paper breakdown →
2007926
2
Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Hit paper breakdown →
2007787
3
The epidermal growth factor receptor family: Biology driving targeted therapeutics
Hit paper breakdown →
2008610
4
The tyrosine kinase inhibitor ZD1839 ("Iressa") inhibits HER2-driven signaling and suppresses the growth of HER2-overexpressing tumor cells.
2001448
5 2011330
6
Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
2003252
7 2007226
8 2006212
9 2001198
10 1998178
11 2010151
12 2007150
13 2010137
14
Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells.
2001130
15 2020125
16 2010122
17 2005113
18 2007113
19 2008108
20 2018108

About Mark M. Moasser

Mark M. Moasser is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Genetics, having authored 115 papers that have together received 7.7k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (40 papers), Monoclonal and Polyclonal Antibodies Research (31 papers), Cancer Treatment and Pharmacology (15 papers), Chronic Lymphocytic Leukemia Research (14 papers), Cell Adhesion Molecules Research (10 papers), Glycosylation and Glycoproteins Research (8 papers), Microtubule and mitosis dynamics (8 papers) and Retinoids in leukemia and cellular processes (8 papers). The work is most often cited by research in Oncology (3.8k citations), Radiology, Nuclear Medicine and Imaging (1.4k citations), Cancer Research (779 citations), Genetics (527 citations) and Pulmonary and Respiratory Medicine (1.5k citations). Mark M. Moasser has collaborated with scholars based in United States, Netherlands and Canada. Frequent co-authors include Matthew J. Wieduwilt, Neal Rosen, Natalia Sergina, Andrea Basso, Kevan M. Shokat, Byron Hann, Jimmy A. Blair, Donghui Wang, Marcia R. Campbell and Dhara N. Amin. Their work appears in journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment, Cancer Research, Clinical Cancer Research and Oncogene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact